Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H29NO4 |
| Molecular Weight | 359.4593 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12CC3=CC=C(OCOC(=O)OC(C)C)C=C3[C@@]4(CCCC[C@]14[H])CCN2
InChI
InChIKey=XUUSKRFBAUMDGN-LMNJBCLMSA-N
InChI=1S/C21H29NO4/c1-14(2)26-20(23)25-13-24-16-7-6-15-11-19-17-5-3-4-8-21(17,9-10-22-19)18(15)12-16/h6-7,12,14,17,19,22H,3-5,8-11,13H2,1-2H3/t17-,19+,21+/m1/s1
| Molecular Formula | C21H29NO4 |
| Molecular Weight | 359.4593 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:37:18 GMT 2023
by
admin
on
Sat Dec 16 11:37:18 GMT 2023
|
| Record UNII |
2P8DBQ9WL3
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
46213529
Created by
admin on Sat Dec 16 11:37:18 GMT 2023 , Edited by admin on Sat Dec 16 11:37:18 GMT 2023
|
PRIMARY | |||
|
1058185-02-6
Created by
admin on Sat Dec 16 11:37:18 GMT 2023 , Edited by admin on Sat Dec 16 11:37:18 GMT 2023
|
PRIMARY | |||
|
2P8DBQ9WL3
Created by
admin on Sat Dec 16 11:37:18 GMT 2023 , Edited by admin on Sat Dec 16 11:37:18 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Green Cross, under license from Kangwon University Pharmaceutical College, is developing GCC-1290K (GC-2101), an oral small molecule dopamine modulator and lead from a series of prodrugs of (+)-3-hydroxymorphinan (3-HM), for the potential treatment of Parkinson's disease. 3-HM is the active compound with a potent neuroprotective activity and a good safety profile. The molecule effectively blocks the degeneration of dopaminergic cells in animal models.
In February 2010 the FDA accepted the IND for this molecule. Phase I study was completed in 2011 and commercialization was expected in 2015.
The global anti-Parkinson`s drug market is expected to reach $3 billion US in 2013. In Korea, approximately 70,000 patients have Parkinson`s disease.
|
